Familial adenomatous polyposis (FAP) is an inherited colorectal cancer predisposition syndrome characterized by development of numerous adenomatous polyps in the large intestine. It is caused most commonly by pathogenic APC variants and, if untreated, carries a very high risk of colorectal cancer. Disease typically begins in adolescence or early adulthood.
NVIDIA and Eli Lilly announced a $1 billion AI co-innovation lab as AI drug discovery expands across research, trials and manufacturing. Companies including Recursion and Tempus are using large biological and clinical datasets to speed development and support precision medicine.
Recursion reported Q4 2025 financial results with $754 million in cash providing runway into early 2028. The company achieved clinical validation of its AI platform with REC-4881 showing meaningful polyp reductions in FAP patients and received its fifth Sanofi milestone payment. Full-year revenue reached $74.7 million while net loss widened to $644.8 million.
Biodexa Pharmaceuticals has licensed MTX240, a Phase 1-ready molecular glue therapy for gastrointestinal stromal tumors from Otsuka. The drug demonstrated preclinical efficacy in resistant tumors and is eligible for orphan drug exclusivity, with clinical trials planned by year-end.
Tempest Therapeutics reported 2025 financial results showing $7.7 million in cash and highlighted clinical progress including 100% complete response rate in TPST-2003 CAR-T trial and multiple FDA designations for amezalpat in hepatocellular carcinoma. The company completed strategic CAR-T asset acquisition and plans Phase 2b registrational study for its lead program in 2026.
Artificial intelligence is accelerating drug discovery from molecule screening to clinical trials, but legal uncertainty over patent ownership and profit distribution threatens to slow progress as the technology reshapes pharmaceutical development.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07199127 |
Duodenal Polyposis Classification in FAP |
RECRUITING | |
| NCT06641310 |
Trial of Exercise Therapy in Familial Adenomatous Polyp (FAP) |
RECRUITING | NA |
| NCT06614738 |
Microbial and Environmental Factors Associated with Polyps Development in Familial Adenomatous Polyposis (MicrobEnvironment in FAP) |
RECRUITING | |
| NCT06578637 |
Investigation of β-hydroxybutyrate Supplementation as Chemoprevention in Familial Adenomatous Polyposis |
RECRUITING | NA |
| NCT06557733 |
An Investigational Drug (TPST-1495) in Patients With Familial Adenomatous Polyposis |
RECRUITING | PHASE2 |
| NCT06545526 |
Chemopreventive Effect of Combination of Celecoxib and Metformin in Patients With Familial Adenomatous Polyposis |
RECRUITING | PHASE3 |
| NCT06538402 |
Ten Versus Fifteen Centimeter Pouch in IPAA Surgery |
RECRUITING | NA |
| NCT06435533 |
Cold Atmospheric Plasma for the Endoscopic Treatment of Duodenal Polyps in Patients With Familial Adenomatous Polyposis |
RECRUITING | NA |
| NCT06308445 |
Safety Study for the Use of Rapamycin in Children With Familial Adenomatous Polyposis |
NOT_YET_RECRUITING | PHASE2 |
| NCT06163365 |
Inherited Cancer Early Diagnosis (ICED) Study |
RECRUITING |
